Morgan Stanley cut shares of GlaxoSmithKline PLC (NYSE:GSK) from an equal weight rating to an underweight rating in a research note issued to investors on Friday, Marketbeat.com reports.

Several other equities research analysts have also issued reports on GSK. J P Morgan Chase & Co reissued a neutral rating on shares of GlaxoSmithKline PLC in a research note on Monday, July 24th. Citigroup Inc. lowered shares of GlaxoSmithKline PLC from a buy rating to a neutral rating in a research note on Wednesday, July 5th. BidaskClub lowered shares of GlaxoSmithKline PLC from a sell rating to a strong sell rating in a research note on Monday, July 24th. Berenberg Bank raised shares of GlaxoSmithKline PLC from a hold rating to a buy rating in a research note on Friday, May 26th. Finally, TheStreet lowered shares of GlaxoSmithKline PLC from a b rating to a c+ rating in a research note on Wednesday, July 26th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating to the company’s stock. GlaxoSmithKline PLC has an average rating of Hold and an average price target of $46.00.

GlaxoSmithKline PLC (NYSE GSK) opened at 40.27 on Friday. The company’s 50-day moving average price is $39.93 and its 200 day moving average price is $41.82. The stock has a market capitalization of $98.42 billion, a P/E ratio of 39.79 and a beta of 1.03. GlaxoSmithKline PLC has a 52-week low of $37.20 and a 52-week high of $44.53.

GlaxoSmithKline PLC (NYSE:GSK) last posted its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. The business had revenue of $9.36 billion for the quarter, compared to analyst estimates of $9.52 billion. On average, equities research analysts predict that GlaxoSmithKline PLC will post $2.87 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Morgan Stanley Lowers GlaxoSmithKline PLC (GSK) to Underweight” was reported by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/09/12/morgan-stanley-lowers-glaxosmithkline-plc-gsk-to-underweight.html.

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be paid a $0.491 dividend. The ex-dividend date is Wednesday, August 9th. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 dividend on an annualized basis and a yield of 4.88%. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is currently 197.00%.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bingham Osborn & Scarborough LLC purchased a new position in GlaxoSmithKline PLC in the 2nd quarter worth approximately $311,000. 10 15 Associates Inc. lifted its stake in GlaxoSmithKline PLC by 6.4% in the 1st quarter. 10 15 Associates Inc. now owns 237,716 shares of the pharmaceutical company’s stock worth $10,022,000 after purchasing an additional 14,247 shares in the last quarter. Lincluden Management Ltd. lifted its stake in GlaxoSmithKline PLC by 1.7% in the 1st quarter. Lincluden Management Ltd. now owns 120,845 shares of the pharmaceutical company’s stock worth $5,095,000 after purchasing an additional 1,990 shares in the last quarter. Anchor Capital Advisors LLC lifted its stake in GlaxoSmithKline PLC by 9.6% in the 1st quarter. Anchor Capital Advisors LLC now owns 613,324 shares of the pharmaceutical company’s stock worth $25,858,000 after purchasing an additional 53,894 shares in the last quarter. Finally, BlueCrest Capital Management Ltd lifted its stake in GlaxoSmithKline PLC by 293.5% in the 1st quarter. BlueCrest Capital Management Ltd now owns 51,157 shares of the pharmaceutical company’s stock worth $2,157,000 after purchasing an additional 38,157 shares in the last quarter. 9.29% of the stock is currently owned by institutional investors and hedge funds.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.